In the current study, the researchers used what is known as fragment-based drug design instead. The method involves first identifying a very small molecule that can bind to the target protein.
The battle against drug resistance in lung cancer therapy remains a critical issue in oncology, with resistance mechanisms ...
Alongside new steps in its therapeutic pipeline—and a new push into laboratory robotics—Insilico Medicine has raised $110 ...
The convergence of AI and drug delivery is opening new frontiers in precision medicine. AI-powered predictive modeling is ...
Using a method known as “rational drug design,” Elion and Hitchings were able to successfully interfere with cell growth, giving way to a number of effective drugs for treating leukemia, gout, malaria ...
Inspired by early biomimetic approaches, Kerem Çamsarı’s work evokes features of neural connectivity
The professor and has team received the prestigious Misha Mahowald Prize in Neuromorphic Engineering for their work on ...
Its deal with the US-based AI-driven drug design and development company will see Cloud design novel small-molecule agents to GSK-specified targets. Ed Addison, CEO of Cloud Pharmaceuticals ...
Azor Biotek is applying artificial intelligence solutions to the design and development of tailored, highly specific, novel small molecules, tapping into the vast potential of RNA drug targets.
A recently identified bacterial protein structure is contributing to the design of novel anticancer drug delivery systems.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback